{"entity":{"id":"nct04489771","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","aka":[],"tldr":"A phase 2 trial of Belzutifan in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) is a phase 2 interventional study registered as NCT04489771 by Merck Sharp & Dohme LLC, with 154 participants enrolled, started 2020-09-13 and due to reach its primary completion in 2023-02-10. Interventions recorded: Belzutifan. Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04489771","url":"https://clinicaltrials.gov/study/NCT04489771"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["belzutifan"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04489771","phase":"2","setting":"Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma","sponsor":"Merck Sharp & Dohme LLC","enrolled":154,"outcomes":[]},"route":"/trials/nct04489771/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}